Long-term efficacy and safety of guselkumab in psoriasis patients with and without psoriatic arthritis: A pooled analysis from VOYAGE 1 and VOYAGE 2 - 22/08/19
A.B. Kimball, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; P. Foley, University of Melbourne, St. Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc, Carlton, VIC, Australia; D. Thaci, Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany; R. Vender, McMaster University, Hamilton, ON, Canada; M. Song, Janssen Research & Development, LLC, Spring House, PA; S. Li, Janssen Research & Development, LLC, Spring House, PA; S. Fakharzadeh, Janssen Scientific Affairs, LLC, Horsham, PA; Y.-K. Shen, Janssen Research & Development, LLC, Spring House, PA; A. Armstrong, Keck School of Medicine, University of Southern California, Los Angeles, CA
Le texte complet de cet article est disponible en PDF. Supported 100% by Janssen Research & Development, LLC. |
Vol 81 - N° 4S1
P. AB233 - octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?